Evidence map›Paper›PMID 35410149›Full record

ArticleBMC public health2022

Survival of eight LLIN brands 6, 12, 24 and 36 months after a mass distribution campaign in rural and urban settings in Senegal.

Mbaye Diouf, Babacar Thiendella Faye, El Hadji Diouf, Abdoulaye Kane Dia, Abdoulaye Konate, Fatou Ba Fall, Doudou Sene, Mame Birame Diouf, Libasse Gadiaga, Lassana Konate and 3 more

Abstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mbaye DioufLaboratory of Vector and Parasite Ecology (UCAD), Dakar, Senegal. bayonly900@hotmail.fr.ORCID 0000-0002-5810-6647
Babacar Thiendella FayeLaboratory of Parasitology (UCAD), Dakar, Senegal.
El Hadji DioufLaboratory of Vector and Parasite Ecology (UCAD), Dakar, Senegal.
Abdoulaye Kane DiaLaboratory of Vector and Parasite Ecology (UCAD), Dakar, Senegal.
Abdoulaye KonateLaboratory of Vector and Parasite Ecology (UCAD), Dakar, Senegal.
Fatou Ba FallNational Malaria Control Program (NMCP/Senegal), Dakar, Senegal.
Doudou SeneNational Malaria Control Program (NMCP/Senegal), Dakar, Senegal.
Mame Birame DioufPresident's Malaria Initiative/ United State Agency International Development/Senegal (USAID/PMI), Dakar, Senegal.
Libasse GadiagaNational Malaria Control Program (NMCP/Senegal), Dakar, Senegal.
Lassana KonateLaboratory of Vector and Parasite Ecology (UCAD), Dakar, Senegal.
Demba Anta DioneHealth and Development Solution-Africa (HDS-Africa/Dakar), Dakar, Senegal.
Roger Clément TinePresident's Malaria Initiative/ United State Agency International Development/Senegal (USAID/PMI), Dakar, Senegal.
Ousmane FayeLaboratory of Vector and Parasite Ecology (UCAD), Dakar, Senegal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong lasting insecticidal nets (LLIN) are one of the core components of global malaria prevention and control. The lifespan of LLIN varies widely depending on the population or environment, and randomized studies are required to compare LLIN inaccording to arbitrary thresholds households under different field conditions. This study investigated survival of different LLIN brands in Senegal.

methodsTen thousand six hundred eight LLINs were distributed in five regions, each stratified by rural and urban setting. As part of the longitudinal follow-up, 2222 nets were randomly sampled and monitored from 6 to 36 months. Using random effects for households, Bayesian models were used to estimate independent survival by net type (Interceptor®, Life Net®, MAGNet™, Netprotect®, Olyset® Net, PermaNet® 2.0 R, PermaNet® 2.0 C, Yorkool® LN) and by area (rural/urban). In addition to survival, median survival time and attrition of each LLIN brand was determined. Attrition was defined as nets that were missing because they were reported given away, destroyed and thrown away, or repurposed.

resultsThree net types had a proportion of survival above 80% after 24 months: Interceptor®87.8% (95% CI 80-93.4); conical PermaNet® 2.0 86.9% (95% CI 79.3-92.4) and Life Net® 85.6% (95% CI 75-93). At 36 months, conical PermaNet® 2.0 maintained a good survival rate, 79.5% (95% CI 65.9-88.8). The attrition due to redistributed nets showed that the two conical net types (PermaNet® 2.0 and Interceptor®) were more often retained by households and their median retention time was well above 3 years (median survival time = 3.5 years for PermaNet® 2.0 and median survival time = 4 years for Interceptor®). Despite this good retention, Interceptor® had weak physical integrity and its median survival due to wear and tear was below 3 years (median survival time = 2.4 years). The odds ratio of survival was 2.5 times higher in rural settings than in urban settings (OR 2.5; 95% CI 1.7-3.7).

conclusionsDifferences in survival among LLIN may be driven by brand, shape or environmental setting. In this study in Senegal, conical PermaNet® 2.0 were retained in households while rectangular PermaNet® 2.0 had lower retention, suggesting that net shape may play a role in retention and should be further investigated. Distribution of preferred LLIN shape, accompanied by good communication on care and repair, could lead to increased effective lifespan, and allow for longer intervals between universal coverage campaigns.

Indexed as

InsecticidesInsecticide-Treated BednetsMalariaBayes TheoremHumansMosquito ControlSenegalInsecticidesLLINMedian survival timeRetentionSenegalSurvival

Identifiers

PMID35410149
PMCPMC9004050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.